1. Home
  2. PDEX vs HURA Comparison

PDEX vs HURA Comparison

Compare PDEX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pro-Dex Inc.

PDEX

Pro-Dex Inc.

HOLD

Current Price

$62.56

Market Cap

197.4M

Sector

Health Care

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.11

Market Cap

160.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDEX
HURA
Founded
1978
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.4M
160.5M
IPO Year
1995
2010

Fundamental Metrics

Financial Performance
Metric
PDEX
HURA
Price
$62.56
$2.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$56.00
$9.50
AVG Volume (30 Days)
62.1K
255.5K
Earning Date
05-01-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
345.00
47.93
EPS
3.27
N/A
Revenue
$66,593,000.00
N/A
Revenue This Year
$7.22
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.83
N/A
Revenue Growth
23.68
N/A
52 Week Low
$23.52
$0.41
52 Week High
$69.86
$3.43

Technical Indicators

Market Signals
Indicator
PDEX
HURA
Relative Strength Index (RSI) 52.18 47.72
Support Level $60.40 $1.99
Resistance Level $68.86 $2.20
Average True Range (ATR) 3.11 0.18
MACD -0.43 -0.01
Stochastic Oscillator 38.20 25.42

Price Performance

Historical Comparison
PDEX
HURA

About PDEX Pro-Dex Inc.

Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: